Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Claudin-6-Directed Cyclic Peptides for Precision Radiotheranostics in Ovarian Cancer
EF 2025-26
Résumé
Ovarian cancer is often called a silent killer because it is generally not detected until it has already spread widely within the abdomen. At this advanced stage, treatment becomes much more difficult, and fewer than 35% of patients survive beyond five years. There is an urgent need for earlier detection methods and more precise, personalized treatments.
The primary objective of our proposed work is to develop a new targeted imaging and treatment platform specifically for ovarian cancer. This platform utilizes a rapidly growing area of medicine called 'Radiotheranostics' that uses the same molecule to both detect and treat cancer. First, the molecule is attached to a small amount of radioactive material to help locate tumors using medical imaging scans like PET/CT. Then, a therapeutic version delivers radiation directly to the cancer while sparing healthy tissues.
We are developing a new radiotheranostic agent that targets a protein called Claudin-6 that is found in large amounts on ovarian cancer cells, but rare in healthy tissues. By developing molecules that can recognize and bind to Claudin-6, we aim to detect ovarian tumors earlier and deliver radiation therapy directly to cancer cells - even those that have spread.
This work will combine advanced techniques in molecular design, peptide chemistry, and imaging technologies to create a personalized platform for ovarian cancer care. If successful, it could lead to earlier diagnosis, better treatment outcomes, and a new generation of targeted therapies for ovarian cancer patients, especially those with an advanced disease. Ultimately, this work aims to reduce mortality and improve the quality of life for women affected by this devastating disease.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
537630
Name
BENDRE SHREYA
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Claudin-6-Directed Cyclic Peptides for Precision Radiotheranostics in Ovarian Cancer
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Cdna Display; Machine Learning; Pet/Ct Imaging; Radiopharmaceutical Chemistry; Radiotheranostics; Spect/Ct Imaging; Targeted Molecular Imaging
Abstract
Ovarian cancer is often called a silent killer because it is generally not detected until it has already spread widely within the abdomen. At this advanced stage, treatment becomes much more difficult, and fewer than 35% of patients survive beyond five years. There is an urgent need for earlier detection methods and more precise, personalized treatments.
The primary objective of our proposed work is to develop a new targeted imaging and treatment platform specifically for ovarian cancer. This platform utilizes a rapidly growing area of medicine called 'Radiotheranostics' that uses the same molecule to both detect and treat cancer. First, the molecule is attached to a small amount of radioactive material to help locate tumors using medical imaging scans like PET/CT. Then, a therapeutic version delivers radiation directly to the cancer while sparing healthy tissues.
We are developing a new radiotheranostic agent that targets a protein called Claudin-6 that is found in large amounts on ovarian cancer cells, but rare in healthy tissues. By developing molecules that can recognize and bind to Claudin-6, we aim to detect ovarian tumors earlier and deliver radiation therapy directly to cancer cells - even those that have spread.
This work will combine advanced techniques in molecular design, peptide chemistry, and imaging technologies to create a personalized platform for ovarian cancer care. If successful, it could lead to earlier diagnosis, better treatment outcomes, and a new generation of targeted therapies for ovarian cancer patients, especially those with an advanced disease. Ultimately, this work aims to reduce mortality and improve the quality of life for women affected by this devastating disease.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
BENDRE, SHREYA
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~